Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

(2013) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells

(2013) S. E. Pratt et al.   CLINICAL CANCER RESEARCH

Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

(2013) S. E. Pratt et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

(2011) Stijn L.W. Koolen et al.   CLINICAL CANCER RESEARCH

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute